J. Craig Venter tells the WorldPost that humans now have the ability to control evolution, though perhaps not yet the wisdom to do it safely.
As newly-minted GenoFAB mulls commercial models for its GenoCAD DNA design web app, the company is trying to engage with its target market through pilot projects.
Gen9 will make new versions of DNA parts for use by iGEM collaborators, including participants in the non-profit's annual student competition.
In Science this week: issues in reproducibility, circulating DNA predicts breast cancer relapse, and more.
The firm sold 5,609,756 shares of its common stock at $41 per share. Proceeds will be used for general corporate purposes and strategic acquisitions or investments.
Synthetic life with extra bases might not only provide new drugs, but also a view into other ways life could evolve, Technology Review reports.
MIT researchers have developed genetic parts that can be used to program gene expression in the commensal gut bacterium Bacteroides thetaiotaomicron.
The funding will support the creation ofAlberta's first synthetic biology maker space at the University of Lethbridge.
The new 8,000-square-foot building will support oligonucleotide manufacturing for molecular biology applications such as qPCR, next-generation sequencing, and synthetic biology.
Genome Compiler will incorporate Addgene's plasmid library into its design software and collaboration platform for synthetic biology.
CBS This Morning highlights recent Medicare fraud involving offers of genetic testing.
Researchers find that many cancer drugs in development don't work quite how their developers thought they did, as Discover's D-brief blog reports.
Mariya Gabriel, a Bulgarian politician, is to be the next European Union research commissioner, according to Science.
In Science this week: a survey indicates that US adults are more likely to support the agricultural use of gene drives if they target non-native species and if they are limited, and more.